Ann Arbor-based Rubicon Genomics Inc. said its ThruPlex-FD prep kits contributed to the success of a study published in Nature that showed that genomic data extracted from the plasma of cancer patients can be used to track drug resistance and potentially guide treatment.
The fatigue experienced by patients undergoing cancer treatments has long been recognized by health care providers, although its causes and ways to manage it are still largely unknown.
A program to match advanced cancer patients with clinical trials that may help where standard treatments fail has grown out of the research lab of University of Michigan Taubman Scholar Arul Chinnaiyan.
Pat Sweeting Reporting We’ve often spoken about the benefits to cancer patients of being able to talk about a diagnosis such as breast cancer with others. But, what about a family member who may also be the caregiver? […]